spacer
home > ebr > spring 2018 > precision healthcare
PUBLICATIONS
European Biopharmaceutical Review

Precision Healthcare

At the end of January, industry observers were brimming with speculation on the likely course of Amazon’s entry into healthcare. Championed by a corporation known for ‘disruptive innovation’ in the technology and retail sectors, this project promises to challenge the status quo in the world’s largest healthcare system that is characterised by a fragmented market, entrenched providers, dysfunctional incentives, and little consumer choice.

The manifesto of this bold project by Amazon, JP Morgan, and Berkshire- Hathaway is both challenging and modest: “Our goal is to benefit [1.2 million] US employees and their families, and potentially all Americans.” In short, the goal is to remake the market for healthcare so it becomes integrated, transparent, equitable, and more affordable. Success would not be measured by immediate financial returns, but by long-term impact. Many analysts saw the venture as the opening gambit in online retail pharmacy. This has been the buzz since Amazon acquired Whole Foods Markets last year. Consumers will derive benefit from the online utility of Amazon, as Alibaba is already proving in China.

Amazon fields best-in-class e-commerce, distribution, fulfilment, and technology. In the industry press, the mantra was ‘bricks and clicks’, but in classic economic theory, such an enterprise could upend the supply chain by disintermediation, while using its purchasing power to lower costs to consumers and achieving dominance by sheer scale and reach. Consumer costs would certainly decrease by leveraging the existing customer base and Amazon skill sets.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a China watcher, and an industry consultant with experience in the biotechnology and biopharmaceutical industries.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement